178 related articles for article (PubMed ID: 37519563)
1. Cytotoxic Lesions of the Corpus Callosum (CLOCC) Suggesting Exacerbation by Heterogeneous COVID-19 Booster Vaccination.
Chiba Y; Takahashi Y; Kawakita R; Deguchi K; Masaki T
Cureus; 2023 Jun; 15(6):e41105. PubMed ID: 37519563
[TBL] [Abstract][Full Text] [Related]
2. A 23-Year-Old Man with SARS-CoV-2 Infection Who Presented with Auditory Hallucinations and Imaging Findings of Cytotoxic Lesions of the Corpus Callosum (CLOCC).
Elkhaled W; Ben Abid F; Akhtar N; Abukamar MR; Ibrahim WH
Am J Case Rep; 2020 Dec; 21():e928798. PubMed ID: 33315854
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic lesions of the corpus callosum after COVID-19 vaccination.
Ohara H; Shimizu H; Kasamatsu T; Kajita A; Uno K; Lai KW; Vellingiri B; Sugie K; Kinoshita M
Neuroradiology; 2022 Oct; 64(10):2085-2089. PubMed ID: 35809100
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 psychosis versus psychosis due to cytotoxic lesion of the corpus callosum (CLOCC): A case report and review.
Levin Y; Imtiaz A; Borja B
Psychiatry Res Case Rep; 2023 Jun; 2(1):100133. PubMed ID: 37251527
[TBL] [Abstract][Full Text] [Related]
5. Non-severe COVID-19 complicated by cytotoxic lesions of the corpus callosum (mild encephalitis/encephalopathy with a reversible splenial lesion): a case report and literature review.
Kubo M; Kubo K; Kobayashi KI; Komiya N
Int J Infect Dis; 2022 Dec; 125():1-9. PubMed ID: 36122669
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic lesions of the corpus callosum: a systematic review.
Moors S; Nakhostin D; Ilchenko D; Kulcsar Z; Starkey J; Winklhofer S; Ineichen BV
Eur Radiol; 2023 Dec; ():. PubMed ID: 38147170
[TBL] [Abstract][Full Text] [Related]
7. Mild Encephalopathy With Partial Reversible Splenium Lesion Associated With SARS-CoV-2 Infection.
Reyes CZA; Kokash A; Yacoub HA
Cureus; 2023 Mar; 15(3):e36421. PubMed ID: 37090308
[TBL] [Abstract][Full Text] [Related]
8. Multisystem Inflammatory-like Syndrome in a Child Following COVID-19 mRNA Vaccination.
Poussaint TY; LaRovere KL; Newburger JW; Chou J; Nigrovic LE; Novak T; Randolph AG
Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062704
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 5-related autoimmune encephalitis with reversible splenial lesion syndrome following SARS-CoV-2 vaccination.
Zhang Y; Lian B; Yang S; Huang X; Zhou Y; Cao L
Medicine (Baltimore); 2023 Feb; 102(7):e32971. PubMed ID: 36800591
[TBL] [Abstract][Full Text] [Related]
10. [Cytotoxic lesion of the corpus callosum (CLOCC) in a context of viral meningitis].
Hoëffelin H; Marchetti P; Khamis J; Reginster P
Rev Med Liege; 2020 Feb; 75(2):78-82. PubMed ID: 32030930
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic lesion of corpus callosum after COVID-19 vaccination: case report.
Chang WL; Cheng CF; Lin SK
Acta Neurol Taiwan; 2024 Jun; 33(2)():68-72. PubMed ID: 37848228
[TBL] [Abstract][Full Text] [Related]
12. Mild encephalitis/encephalopathy with a reversible splenial lesion associated with systemic Mycoplasma pneumoniae infection in North America: a case report.
Talukder NT; Feezel A; Lankford JE
J Med Case Rep; 2022 Feb; 16(1):74. PubMed ID: 35183255
[TBL] [Abstract][Full Text] [Related]
13. "Reversible cytotoxic lesion of the corpus callosum following SARS-CoV-2 mRNA vaccine administration: a finding to be aware of".
Procaccini L; Mincuzzi E; Bernardini A; Franchi P; Voicu IP; Caulo M
Neuroradiol J; 2022 Dec; 35(6):758-762. PubMed ID: 35488375
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic Lesion of the Corpus Callosum Caused by Puumala Hantavirus Infection.
Lebecque O; Mulquin N; Dupont M
J Belg Soc Radiol; 2019 Jan; 103(1):11. PubMed ID: 30693350
[TBL] [Abstract][Full Text] [Related]
15. Mild encephalitis/encephalopathy with a reversible splenial lesion secondary to encephalitis complicated by hyponatremia: A case report and literature review.
Shi BC; Li J; Jiang JW; Li MX; Zhang J; Shang XL
Medicine (Baltimore); 2019 Nov; 98(47):e17982. PubMed ID: 31764808
[TBL] [Abstract][Full Text] [Related]
16. An Equivocal SCC Lesion-Antiepileptic-Induced CLOCC.
Kuczyńska M; Zbroja M; Cyranka W; Halczuk I; Kopyto E; Halczuk I; Drelich-Zbroja A
Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326340
[TBL] [Abstract][Full Text] [Related]
17. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
Sriwastava S; Tandon M; Podury S; Prasad A; Wen S; Guthrie G; Kakara M; Jaiswal S; Subedi R; Elkhooly M; Lisak RP
J Neurol; 2021 Dec; 268(12):4448-4478. PubMed ID: 34009454
[TBL] [Abstract][Full Text] [Related]
19. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
